Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis

dc.creatorKanevsky, Diego
dc.creatorElgart, Jorge Federico
dc.creatorZerga, Marta
dc.creatorGlancszpigel, Mariana
dc.creatorMorisset, Pierre
dc.date2022-06
dc.date2023-08-29T13:33:59Z
dc.date.accessioned2024-07-24T03:47:00Z
dc.date.available2024-07-24T03:47:00Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/156981
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9535169
dc.descriptionThe aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina.
dc.descriptionXXVII Congress of the European Hematology Association (Viena, 9 al 17 de junio de 2022)
dc.descriptionCentro de Endocrinología Experimental y Aplicada
dc.formatapplication/pdf
dc.format3004-3005
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.subjectCiencias Médicas
dc.subjectvenetoclax plus obinutuzumab
dc.subjectlymphocytic leukemia
dc.titleVenetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
dc.typeArticulo
dc.typeArticulo


Este ítem pertenece a la siguiente institución